Cite
Velthuizen ME, van der Luijt RB, de Vries BJ, et al. Recontacting non-BRCA1/2 breast cancer patients for germline CHEK2 c.1100del pathogenic variant testing: uptake and patient experiences. Hered Cancer Clin Pract. 2021;19(1):9doi: 10.1186/s13053-021-00166-1.
Velthuizen, M. E., van der Luijt, R. B., de Vries, B. J., Koudijs, M. J., Bleiker, E. M. A., & Ausems, M. G. E. M. (2021). Recontacting non-BRCA1/2 breast cancer patients for germline CHEK2 c.1100del pathogenic variant testing: uptake and patient experiences. Hereditary cancer in clinical practice, 19(1), 9. https://doi.org/10.1186/s13053-021-00166-1
Velthuizen, Mary E, et al. "Recontacting non-BRCA1/2 breast cancer patients for germline CHEK2 c.1100del pathogenic variant testing: uptake and patient experiences." Hereditary cancer in clinical practice vol. 19,1 (2021): 9. doi: https://doi.org/10.1186/s13053-021-00166-1
Velthuizen ME, van der Luijt RB, de Vries BJ, Koudijs MJ, Bleiker EMA, Ausems MGEM. Recontacting non-BRCA1/2 breast cancer patients for germline CHEK2 c.1100del pathogenic variant testing: uptake and patient experiences. Hered Cancer Clin Pract. 2021 Jan 19;19(1):9. doi: 10.1186/s13053-021-00166-1. PMID: 33468213; PMCID: PMC7814590.
Copy
Download .nbib
